ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.

by Eva-Maria Ratai, Zheng Zhang, James Fink, Mark Muzi, Lucy Hanna, Erin Greco, Todd Richards, Daniel Kim, Ovidiu C Andronesi, Akiva Mintz, Lale Kostakoglu, Melissa Prah, Benjamin Ellingson, Kathleen Schmainda, Gregory Sorensen, Daniel Barboriak, David Mankoff, Elizabeth R Gerstner, ACRIN 6684 trial group
Published 2018-01-01